anurajms/meta_analysis huggingface dataset:
outcomes:
Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome
1. All Cause Mortality 2. Costs and Cost Analysis 3. Hemodynamic test 4. Quality of Life 5. Hospitalization 6. Adverse Event
outcomes:
Ivabradine as adjuvant treatment for chronic heart failure
1. Exercise Tolerance Test 2. Costs and Cost Analysis 3. Quality of Life 4. Death 5. Hospitalization 6. Adverse Event
outcomes:
Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension
1. Withdrawn From Research Study 2. Myocardial Infarction 3. All Cause Mortality 4. End Stage Kidney Disease 5. Stroke 6. Congestive Heart Failure 7. Serious Adverse Event 8. Cardiovascular Event 9. Blood Pressure Alteration 10. Hospitalization 11. Alteration In Heart Rate 12. Adverse Event
outcomes:
Electromechanical‐assisted training for walking after stroke
1. Independent Walking 2. Functional Ambulation Category 3. Patient compliance 4. Walking ability
outcomes:
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
1. All Cause Mortality 2. Stroke 3. Myocardial Infarction 4. Cardiovascular disease
outcomes:
Pentoxifylline for intermittent claudication
1. Quality of Life 2. Adverse Event 3. Walking Distance 4. Walking ability
outcomes:
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
1. Stroke 2. Visual Analog Scale 3. Death 4. Haemorrhage 5. Thromboembolic Event 6. Adverse Event 7. Major Bleed
outcomes:
Vena caval filters for the prevention of pulmonary embolism
1. Complication 2. Death 3. Pulmonary Embolism 4. Major Bleed
outcomes:
Atherectomy for peripheral arterial disease
1. All Cause Mortality 2. Artery revascularisation 3. Cardiovascular Event 4. Target vessel revascularisation 5. Complication 6. Primary Patency
outcomes:
Motor imagery for gait rehabilitation after stroke
1. Functional Independence Measure 2. Motor Assessment Scale 3. Rivermead Motor Assessment 4. Functional Capacity Evaluation 5. Adverse Event 6. Modified Barthel Index Of Activities Of Daily Living
outcomes:
Presurgery exercise‐based conditioning interventions (prehabilitation) in adults undergoing lower limb surgery for peripheral arterial disease
1. Surgical Site Infection 2. All Cause Mortality 3. Postoperative pulmonary complication 4. Cardiovascular Event 5. Complication 6. Readmission 7. Hemorrhage
outcomes:
Alcohol intake reduction for controlling hypertension
1. Finding Of Decreased Blood Pressure 2. All Cause Mortality 3. Serious Adverse Event 4. Systolic Blood Pressure 5. Cardiovascular Event 6. Cardiovascular Mortality
outcomes:
Time course for blood pressure lowering of beta‐blockers with partial agonist activity
1. Systolic Blood Pressure 2. Diastolic Blood Pressure
outcomes:
Citicoline for treating people with acute ischemic stroke
1. Activities of Daily Living 2. Disability 3. All Cause Mortality 4. Serious Adverse Event 5. Quality of Life 6. Rankin Disability Scale
outcomes:
Modes of exercise training for intermittent claudication
1. Functional Movement Disorder 2. Health-Related Quality of Life 3. Walking Distance 4. Patient-Reported Outcome
outcomes:
Setting and techniques for monitoring blood pressure during pregnancy
1. Blood pressure measurement 2. Hospital admission 3. Stillbirth 4. Length Of Stay 5. Induction Of Labor 6. Neonatal Death 7. Perinatal Death 8. Pre-eclampsia 9. Birth Outcome 10. Maternal Death 11. Endotracheal intubation 12. Intensive Care 13. Mechanical ventilation
outcomes:
mHealth education interventions in heart failure
1. Self Efficacy 2. Patient knowledge 3. Quality of Life 4. Hospitalization 5. Adverse Event 6. Self-care practice
outcomes:
Effect of alcohol on blood pressure
1. Blood Pressure Alteration 2. Alteration In Heart Rate
outcomes:
Surgery for small asymptomatic abdominal aortic aneurysms
1. Costs and Cost Analysis 2. Quality of Life 3. Death 4. Life expectancy shortened 5. Ruptured Aortic Aneurysm
outcomes:
Mechanical assist devices for acute cardiogenic shock
1. Dialysis result 2. Quality of Life 3. Hospitalization 4. Adverse Event
outcomes:
Mental practice for treating upper extremity deficits in individuals with hemiparesis after stroke
1. Action Research Arm Test 2. Box and Block test 3. Wolf Motor Function Test 4. Motor Activity Log
outcomes:
A comparison of different antibiotic regimens for the treatment of infective endocarditis
1. Infection 2. All Cause Mortality 3. Disease Condition Determination, Cured 4. Congestive Heart Failure 5. Endocarditis 6. Quality of Life 7. Septic embolus 8. Cardiac surgery 9. Adverse Event
outcomes:
Anti‐inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or transient ischaemic attack
1. Infection 2. Myocardial Infarction 3. Stroke 4. Serious Adverse Event 5. Cardiac Arrest 6. Cardiovascular Mortality 7. Impending infarction
outcomes:
Pharmacological, psychological and non‐invasive brain stimulation interventions for preventing depression after stroke
1. Disability 2. Minor Depressive Disorder 3. Cognitive function 4. Social activity 5. Dysthymia 6. Psychological distress 7. Death 8. Depression 9. Activities Of Daily Living Assessment
outcomes:
Pharmacological treatment for Buerger's disease
1. Pain 2. Amputation 3. Ulcer 4. Healing 5. Pain Relief
outcomes:
Interventions for sexual dysfunction following stroke
1. Sexual Satisfaction Scale for Women 2. Sexual Self-Perception and Adjustment Questionnaire 3. Changes in Sexual Functioning Short-Form 4. International Index Of Erectile Function 5. Sexual Function Questionnaire 6. Arizona Sexual Experience Scale 7. Derogatis Sexual Functioning Inventory
outcomes:
Transverse versus vertical groin incision for femoral artery approach
1. Surgical Site Infection 2. Vascular Graft Infection 3. Finding Of Lymph Node And Lymphatics 4. Repeat surgery 5. Lymphatic Incision 6. Neurological Deficit 7. Death 8. Hospitalization
outcomes:
Low molecular weight heparin for prevention of microvascular occlusion in digital replantation
1. Treatment Success 2. Wound Hemorrhage 3. Venous Occlusion 4. Abnormal Vascular Flow 5. Arterial occlusion
outcomes:
Treatment of distal deep vein thrombosis
1. All Cause Mortality 2. Disease Recurrence 3. Death 4. Pulmonary Embolism 5. Recurrent Deep Vein Thrombosis 6. Haemorrhage 7. Thromboembolism 8. Major Bleed
outcomes:
Physical fitness training for stroke patients
1. Disability 2. Physical fitness 3. All Cause Mortality 4. Finding Of Gait 5. Dependence 6. Death
outcomes:
Advance care planning for adults with heart failure
1. Decisional Conflict 2. Communication skills 3. Hospice Care 4. Nursing Documentation 5. Attitude 6. Quality of Life 7. Depression 8. Death 9. End Of Life Care Planning 10. Intubation 11. Patient Satisfaction
outcomes:
Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis
1. Stroke 2. Myocardial Infarction 3. Death
outcomes:
Anticoagulant treatment for subsegmental pulmonary embolism
1. All Cause Mortality 2. At Risk Of Venous Thromboembolus 3. Major Bleed
outcomes:
First‐line combination therapy versus first‐line monotherapy for primary hypertension
1. Stroke 2. Congestive Heart Failure 3. Sudden Death 4. Hospitalization 5. Adverse Event 6. Congenital Malformation 7. Disability 8. Withdrawn From Research Study 9. All Cause Mortality 10. Myocardial Infarction 11. Blood Pressure Alteration 12. Intracranial Haemorrhage Ruptured Aneurysm 13. Death 14. Cardiovascular Morbidity
outcomes:
Dressings and topical agents for arterial leg ulcers
1. Morbidity Index 2. Quality of Life 3. Complication 4. Ulcer 5. Healing 6. Time-to-Event 7. Patient Satisfaction
outcomes:
Motor neuroprosthesis for promoting recovery of function after stroke
1. Activities of Daily Living 2. Jebsen Hand Function Test 3. Rivermead Activities Of Daily Living Index 4. Extremities - General 5. Functional Independence Measure 6. Timed Up And Go Mobility Test 7. Dynamic Gait Index 8. Motor Assessment Scale 9. Nine Hole Peg Test 10. Barthel Index
outcomes:
Endovascular versus open repair of asymptomatic popliteal artery aneurysm
1. Duration Of Surgery 2. Duration Of Hospital Stay 3. Primary Patency
outcomes:
Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis
1. All Cause Mortality 2. Stroke 3. Myocardial Infarction 4. Coronary Artery Stent Thrombosis 5. Cardiovascular Mortality 6. Major Bleed
outcomes:
Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk
1. Myocardial Infarction 2. Stroke 3. All Cause Mortality 4. Implantation Of Permanent Intravenous Cardiac Pacemaker 5. Cardiac Death 6. Duration Of Hospital Stay 7. Hospitalization
outcomes:
Beta‐blockers for suspected or diagnosed acute myocardial infarction
1. Cardiovascular finding 2. Myocardial Infarction 3. All Cause Mortality 4. Cardiovascular Event 5. Angina Pectoris 6. Quality of Life 7. Death 8. Cardiovascular Mortality 9. Adverse Event
outcomes:
Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure
1. Blood pressure measurement 2. Echocardiography 3. Apnoea Test 4. Cardiovascular Mortality 5. Hospitalization 6. General Body State Finding 7. Adverse Event 8. All Cause Mortality 9. Quality of Life 10. Left Ventricular Ejection Fraction 11. Death 12. Respiratory finding 13. Oxygen Saturation Decreased
outcomes:
Cognitive rehabilitation for attention deficits following stroke
1. Selective attention 2. Mental Alertness 3. Divided attention 4. Short Form Health Survey - 36 5. Change in sustained attention 6. Rating Scale Of Attentional Behavior 7. Attention Rating and Monitoring Scale 8. Depression 9. Cognitive Failures Questionnaire 10. Mars - Moss Attention Rating Scale 11. Functional ability
outcomes:
Combined proximal descending aortic endografting plus distal bare metal stenting (PETTICOAT technique) versus conventional proximal descending aortic stent graft repair for complicated type B aortic dissections
1. All Cause Mortality 2. Thoracic aortic expansion 3. Endoleak 4. Death
outcomes:
Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity in adults undergoing non‐cardiac surgery
1. All Cause Mortality 2. Bradycardia 3. Ecg: Ventricular Arrhythmia 4. Atrial Flutter 5. Cerebrovascular Events 6. Low Blood Pressure 7. Atrial Fibrillation 8. Acute Myocardial Infarction
outcomes:
Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity in adults undergoing cardiac surgery
1. All Cause Mortality 2. Bradycardia 3. Ecg: Ventricular Arrhythmia 4. Atrial Flutter 5. Cerebrovascular Events 6. Low Blood Pressure 7. Atrial Fibrillation 8. Acute Myocardial Infarction
outcomes:
Compression therapy for treating post‐thrombotic syndrome
1. Post-thrombotic syndrome 2. Patient-Reported Outcome
outcomes:
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation
1. Stroke 2. All Cause Mortality 3. Disease Recurrence 4. Atrial Arrhythmia 5. Withdrawal Due To Adverse Events 6. Adverse Event
outcomes:
Interventions for visual field defects in people with stroke
1. Nottingham Extended Activities Of Daily Living Index 2. Perimetry 3. Social Functioning Questionnaire 4. Adverse Event 5. Difficulty Reading 6. Quality Of Wellbeing Scale 7. Assessment Using Hospital Anxiety And Depression Scale 8. Rivermead Activities Of Daily Living Index 9. Confrontation (visual) Test 10. Modified Rankin Scale 11. Berg Balance Scale 12. Humphrey Perimeter Plot 13. Goldmann Perimetry 14. Frenchay Activities Index 15. Tinetti Falls Efficacy Scale 16. Functional Reach Test 17. Functional Independence Measure 18. Tangent Screen Testing 19. Health-Related Quality of Life 20. Katz Activities Of Daily Living 21. Death 22. General Health Questionnaire 23. Geriatric Depression Scale 24. Get Up And Go Test 25. Modified Barthel Index Of Activities Of Daily Living 26. Beck Depression Inventory
outcomes:
Stem cell transplantation for ischemic stroke
1. Infection 2. Disability 3. National Institutes Of Health Stroke Scale 4. All Cause Mortality 5. Neurological Impairment 6. Modified Rankin Scale 7. Physical Functional Dependency 8. Barthel Index
outcomes:
Prostacyclin for pulmonary arterial hypertension
1. Headache 2. Pulmonary Vascular Resistance 3. Dyspnea 4. 6-minute Walk Test 5. Right Atrial Pressure 6. Quality of Life 7. Death 8. Cardiac Index 9. Pulmonary arterial pressure 10. Nyha - New York Heart Association Classification 11. World Health Organisation Functional Class
outcomes:
Non‐invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema
1. Treatment Failure 2. Length Of Stay 3. Death 4. Arterial Blood Gases 5. Recommendation To Discontinue A Procedure 6. Adverse Event 7. Vital Signs 8. Endotracheal intubation 9. Acute Myocardial Infarction
outcomes:
Epidural analgesia for adults undergoing cardiac surgery with or without cardiopulmonary bypass
1. Pneumonia 2. Anaesthetic complication pulmonary 3. Neurological Complication Of Procedure 4. Vasopressins Injectable Suspension 5. Atrial Flutter 6. Endotracheal intubation 7. Postoperative Pain 8. Myocardial Infarction 9. Epidural Hematoma 10. Haemodynamic Monitoring 11. Death 12. Inotropic agent 13. Atrial Fibrillation
outcomes:
Calcium antagonists for acute ischemic stroke
1. Stroke 2. Death 3. Low Blood Pressure 4. Adverse Event 5. Physical Functional Dependency
outcomes:
Exercise‐based cardiac rehabilitation for adult patients with an implantable cardioverter defibrillator
1. Shock 2. All Cause Mortality 3. Costs and Cost Analysis 4. Exercise Test Finding 5. Employment Issues 6. Cardiac Resynchronisation Therapy Implantable Pacemaker 7. Adverse Event 8. Health-Related Quality of Life
outcomes:
Thoracic endovascular repair (TEVAR) versus open surgery for blunt traumatic thoracic aortic injury
1. Death
outcomes:
Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in‐stent restenosis of the femoropopliteal arteries
1. Amputation 2. Death 3. Limb Revascularization
outcomes:
Clinically‐indicated replacement versus routine replacement of peripheral venous catheters
1. Costs and Cost Analysis 2. Thrombophlebitis
outcomes:
Disease management interventions for heart failure
1. All Cause Mortality 2. Costs and Cost Analysis 3. Heart Failure 4. Quality of Life 5. Death 6. Readmission 7. Adverse Event
outcomes:
Angioplasty versus stenting for infrapopliteal arterial lesions in chronic limb‐threatening ischaemia
1. Intention to treat 2. Residual stenosis 3. Complication 4. Death 5. Secondary Patency 6. Primary Patency
outcomes:
Implantable cardiac defibrillators for people with non‐ischaemic cardiomyopathy
1. All Cause Mortality 2. Costs and Cost Analysis 3. Sudden Cardiac Death 4. Quality of Life 5. Death 6. Hospitalization 7. Adverse Event
outcomes:
Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events
1. Stroke 2. Cardiovascular Event 3. Cardiovascular Mortality 4. Hospitalization 5. Adverse Event 6. Myocardial Infarction 7. All Cause Mortality 8. Serious Adverse Event 9. Ischemic Stroke 10. Cardiac Death 11. Quality of Life 12. Coronary Revascularisation 13. Cholesterol Screening
outcomes:
First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for hypertension
1. All Cause Mortality 2. End Stage Kidney Disease 3. Myocardial Infarction 4. Stroke 5. Serious Adverse Event 6. Congestive Heart Failure 7. Blood Pressure Alteration 8. Alteration In Heart Rate 9. Hospitalization
outcomes:
Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease)
1. Pain 2. Event-Free Survival 3. Amputation 4. Evaluation Of Ulcer Healing 5. Adverse Event
outcomes:
Gamma aminobutyric acid (GABA) receptor agonists for acute stroke
1. Functionally Independent 2. Death 3. Adverse Event 4. Barthel Index
outcomes:
Percutaneous vascular interventions versus intravenous thrombolytic treatment for acute ischaemic stroke
1. Modified Rankin Scale 2. Death 3. Intracranial Hemorrhage 4. Perfusion Finding
outcomes:
Very early versus delayed mobilisation after stroke
1. Activities of Daily Living 2. Quality of Life 3. Health Status Index 4. Death 5. Length Of Stay 6. Hospitalization 7. Physical Functional Dependency 8. Barthel Index
outcomes:
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy
1. Small For Gestational Age 2. Stillbirth 3. Induction Of Labor 4. Neonatal Death 5. Perinatal Death 6. Pre-eclampsia 7. Maternal Death 8. Cesarean Section 9. Premature Delivery 10. Fetal Death 11. Eclampsia 12. Withdrawal Due To Adverse Events 13. Intensive Care 14. Miscarriage 15. Cerebral Palsy 16. Hypertensive disorder 17. Proteinuria
outcomes:
Exercise‐based cardiac rehabilitation for people with implantable ventricular assist devices
1. Costs and Cost Analysis 2. Exercise Test Finding 3. Heart Transplant 4. Quality of Life 5. Death 6. Hospitalization 7. Adverse Event
outcomes:
Electromechanical and robot‐assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke
1. Activities of Daily Living 2. Functional Independence Measure 3. Barthel Index
outcomes:
Mechanical versus manual chest compressions for cardiac arrest
1. Hospital discharge 2. Pneumothorax 3. Signs Of Return Of Spontaneous Circulation 4. Sternum fracture 5. Internal Injury Of Abdominal Organs 6. Hemothorax 7. Rib fracture 8. Survival 9. Emergency Hospital Admission
outcomes:
Endovascular coiling versus neurosurgical clipping for people with aneurysmal subarachnoid haemorrhage
1. Modified Rankin Scale 2. Death 3. Glasgow Outcome Scale
outcomes:
Surgery versus thrombolysis for initial management of acute limb ischaemia
1. Stroke 2. Limb Salvage 3. Distal Embolization 4. Peripheral Blood Flow 5. Amputation 6. Death 7. Hemorrhage
outcomes:
Activity monitors for increasing physical activity in adult stroke survivors
1. Daily step count 2. Physical Activity Assessment 3. Walking ability 4. Walking Distance 5. Moderate-to-vigorous intensity physical activity
outcomes:
Blood pressure‐lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack
1. Stroke 2. Not reported
outcomes:
Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non‐cardiac surgery
1. All Cause Mortality
outcomes:
Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies
1. Minor Bleed 2. Quality of Life 3. Death 4. Contusion 5. Haemorrhage 6. Thrombosis 7. Adverse Event 8. Major Bleed
outcomes:
Mirror therapy for improving motor function after stroke
1. Extremities - General 2. Berg Balance Scale 3. Motor Assessment Scale 4. Rivermead Motor Assessment
outcomes:
Remote ischaemic conditioning for preventing and treating ischaemic stroke
1. Impairment Of Psychological Status 2. Cardiovascular Event 3. Neurological Impairment 4. Ischemic Stroke 5. Dependence 6. Death 7. Adverse Event 8. Cognitive impairment
outcomes:
Controlled hypotension versus normotensive resuscitation strategy for people with ruptured abdominal aortic aneurysm
1. Blood Transfusion 2. Blood Coagulation Disorder 3. Death
outcomes:
Extracorporeal shock wave therapy for the healing and management of venous leg ulcers
1. Venous leg ulcer 2. Wound Healing 3. Adverse Event
outcomes:
Transradial versus transfemoral approach for diagnostic coronary angiography and percutaneous coronary intervention in people with coronary artery disease
1. Myocardial Infarction 2. Cardiac Death 3. Adverse Event
outcomes:
First‐line drugs for hypertension
1. All Cause Mortality 2. Stroke 3. Myocardial Infarction 4. Congestive Heart Failure 5. Cardiovascular Event 6. Coronary Heart Disease 7. Sudden Cardiac Death 8. Death 9. Hospitalization 10. Withdrawal Due To Adverse Events 11. Ruptured cerebral aneurysm
outcomes:
Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication
1. Quality of Life 2. Walking Distance 3. Walking ability 4. Patient-Reported Outcome
outcomes:
Perioperative beta‐blockers for preventing surgery‐related mortality and morbidity
1. Death
outcomes:
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
1. Hemorrhagic Cerebral Infarction 2. Ischemic Stroke 3. Embolism
outcomes:
Fluvastatin for lowering lipids
1. Withdrawn From Research Study 2. High Density Lipoprotein Cholesterol Measurement 3. Triglycerides Measurement 4. Total Cholesterol Measurement 5. Low Density Lipoprotein Cholesterol Measurement 6. Adverse Event
outcomes:
Treatment for superficial thrombophlebitis of the leg
1. Disease Recurrence 2. Superficial Thrombophlebitis 3. Minor Bleed 4. Venous Thrombosis 5. Death 6. Adverse Event 7. Major Bleed
outcomes:
Graft type for femoro‐popliteal bypass surgery
1. Limb Salvage
outcomes:
Pulmonary artery perfusion versus no perfusion during cardiopulmonary bypass for open heart surgery in adults
1. All Cause Mortality 2. Adverse Event
outcomes:
Exercise‐based cardiac rehabilitation for adults with stable angina
1. Costs and Cost Analysis 2. Angina Pectoris 3. Exercise Test Finding 4. Quality of Life 5. Death 6. Hospitalization 7. Adverse Event 8. Return to Work
outcomes:
Antibiotic therapy for preventing infections in people with acute stroke
1. Infection 2. Activities of Daily Living 3. Pneumonia 4. Dependence 5. Death 6. Rankin Disability Scale 7. Temperature
outcomes:
Prostanoids for critical limb ischaemia
1. Amputation 2. Quality of Life 3. Cardiovascular Mortality 4. Healing 5. Adverse Event 6. Pain Relief
outcomes:
Home versus in‐patient treatment for deep vein thrombosis
1. Costs and Cost Analysis 2. Minor Bleed 3. Venous Thrombosis 4. Quality of Life 5. Gangrene 6. Death 7. Pulmonary Embolism 8. Heparin 9. Deep Venous Thrombosis 10. Major Bleed 11. Patient Satisfaction
outcomes:
Exercise for intermittent claudication
1. Amputation 2. Quality of Life 3. Death 4. Walking Distance
outcomes:
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
1. Stroke 2. Myocardial Infarction 3. All Cause Mortality 4. Minor Bleed 5. Venous Thrombosis 6. Symptomatic Venous Thromboembolism 7. Major Bleed
outcomes:
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events
1. Myocardial Infarction 2. Death 3. Coronary Revascularisation 4. Adverse Event 5. Limb amputation
outcomes:
Calcium channel blockers for primary and secondary Raynaud's phenomenon
1. Disability 2. Raynaud's Phenomenon 3. Serious Adverse Event 4. Pain 5. Withdrawal Due To Adverse Events
outcomes:
Thrombolysis for acute upper extremity deep vein thrombosis
1. All Cause Mortality 2. Pulmonary Embolism 3. Haemorrhage
outcomes:
Pentasaccharides for the treatment of deep vein thrombosis
1. All Cause Mortality 2. Venous Thrombosis 3. Heparin-induced Thrombocytopenia 4. Adverse Event 5. Major Bleed
outcomes:
Virtual reality for stroke rehabilitation
1. Extremities - General
outcomes:
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease
1. Myocardial Infarction 2. Stroke 3. All Cause Mortality 4. Systemic embolic event 5. Minor Bleed 6. Intracranial Hemorrhage 7. Gastrointestinal Bleeding 8. Major Bleed
outcomes:
Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia
1. Relapse 2. Sinus Rhythm 3. Hospitalization 4. Adverse Event 5. Patient Satisfaction
outcomes:
Compression therapy for prevention of post‐thrombotic syndrome
1. Post-thrombotic syndrome 2. Quality of Life 3. Venous Thrombosis 4. Adverse Event 5. Patient Satisfaction
outcomes:
Interventions for treating tuberculous pericarditis
1. Pericarditis 2. All Cause Mortality 3. Pericardiocentesis 4. Constrictive Pericarditis 5. Cancer
outcomes:
Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome
1. Cardiovascular finding 2. Quality of Life 3. Death 4. Coronary Revascularisation 5. Thrombosis 6. Adverse Event
outcomes:
Treadmill training and body weight support for walking after stroke
1. Assessment Of Ability To Walk 2. Functional Independence Measure 3. Motor Assessment Scale 4. Rivermead Motor Assessment 5. Barthel Index
outcomes:
Pharmacotherapy for hypertension in adults aged 18 to 59 years
1. Stroke 2. Congestive Heart Failure 3. Coronary Heart Disease 4. Cardiovascular Mortality 5. Sudden Death 6. Hospitalization 7. Adverse Event 8. Ruptured cerebral aneurysm 9. Withdrawn From Research Study 10. Myocardial Infarction 11. All Cause Mortality 12. Blood Pressure Alteration 13. Surgery 14. Accelerated And Malignant Hypertension 15. Transient Cerebral Ischemia
outcomes:
Blood pressure targets for hypertension in older adults
1. Stroke 2. Congestive Heart Failure 3. Angina Pectoris 4. Aortic Aneurysm 5. Sudden Death 6. Adverse Event 7. Hemorrhage 8. Renal Failure 9. Withdrawn From Research Study 10. Institutionalized 11. All Cause Mortality 12. Myocardial Infarction 13. Serious Adverse Event 14. Blood Pressure Alteration 15. Heart disease 16. Cerebrovascular Disease 17. Infarction 18. Living In Nursing Home 19. Arterial occlusion 20. Transient Cerebral Ischemia
outcomes:
Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization
1. Venous Thrombosis 2. Death 3. Pulmonary Embolism 4. Adverse Event 5. Deep Venous Thrombosis
outcomes:
Vitamin K antagonists versus low‐molecular‐weight heparin for the long term treatment of symptomatic venous thromboembolism
1. Venogram Abnormal 2. Intraluminal filling defect 3. Symptomatic Recurrent Venous Thrombosis 4. Death 5. Major Bleed
outcomes:
Occupational therapy for adults with problems in activities of daily living after stroke
1. Activities of Daily Living 2. Functional Independence Measure 3. Death 4. Barthel Index
outcomes:
Early supported discharge services for people with acute stroke
1. Institutionalized 2. Death 3. Length Of Stay 4. Duration Of Hospital Stay 5. Hospitalization 6. Extended Activities Of Daily Living Scale 7. Physical Functional Dependency 8. Patient Satisfaction
outcomes:
Psychological interventions for acute pain after open heart surgery
1. Mental Distress 2. Pain 3. Analgesics 4. Mobility function 5. Visual Analog Scale 6. Time-to-Event 7. Extubation 8. Pain Intensity 9. Patient-Reported Outcome
outcomes:
Niacin for primary and secondary prevention of cardiovascular events
1. Treatment Withdrawal 2. Myocardial Infarction 3. Adverse Drug Reaction 4. Stroke 5. Costs and Cost Analysis 6. Quality of Life 7. Death 8. Coronary Revascularisation
outcomes:
Growth factors for angiogenesis in peripheral arterial disease
1. Serious Adverse Event 2. Death 3. Adverse Event 4. Limb amputation
outcomes:
Circuit class therapy for improving mobility after stroke
1. 6-minute Walk Test 2. Assessment Of Ability To Walk
outcomes:
Laparoscopic surgery for elective abdominal aortic aneurysm repair
1. All Cause Mortality 2. Length Of Stay 3. Death 4. Complication 5. Lower Limb Ischemia
outcomes:
Complete versus culprit‐only revascularisation in ST elevation myocardial infarction with multi‐vessel disease
1. Myocardial Infarction 2. Costs and Cost Analysis 3. Quality of Life 4. Death 5. Coronary Revascularisation 6. Adverse Event
outcomes:
Nitric oxide donors (nitrates), L‐arginine, or nitric oxide synthase inhibitors for acute stroke
1. Death 2. Rankin Disability Scale
outcomes:
Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
1. Decisional Conflict 2. Stroke 3. Costs and Cost Analysis 4. Patient knowledge 5. Psychological Finding 6. Psychological Finding Of Perception 7. Quality of Life 8. Medication adherence 9. Thromboembolic Event 10. Patient Satisfaction 11. Major Bleed
outcomes:
Blood pressure lowering efficacy of renin inhibitors for primary hypertension
1. Withdrawn From Research Study 2. Dry Cough 3. All Cause Mortality 4. Serious Adverse Event 5. Blood Pressure Alteration 6. Angioedema 7. Diarrhea 8. Alteration In Heart Rate 9. Adverse Event
outcomes:
Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke
1. All Cause Mortality 2. Death 3. Pulmonary Embolism 4. Deep Venous Thrombosis
outcomes:
Exercise‐based cardiac rehabilitation in heart transplant recipients
1. Exercise Tolerance Test 2. Costs and Cost Analysis 3. Quality of Life 4. Health-related Behavior Finding 5. Death 6. Hospitalization 7. Adverse Event 8. Return to Work
outcomes:
Continuous chest compression versus interrupted chest compression for cardiopulmonary resuscitation of non‐asphyxial out‐of‐hospital cardiac arrest
1. Overall Survival 2. Cardiovascular Mortality
outcomes:
Vitamin C supplementation for the primary prevention of cardiovascular disease
1. Cardiovascular finding 2. Stroke 3. Costs and Cost Analysis 4. Coronary Heart Disease 5. Lipid Tests 6. Angina Pectoris 7. Peripheral Arterial Disease 8. Adverse Event 9. Coronary artery bypass surgery 10. Myocardial Infarction 11. Percutaneous Transluminal Coronary Angioplasty 12. Type 2 Diabetes Mellitus 13. Blood Pressure 14. Quality of Life 15. Death
outcomes:
Risk scoring for the primary prevention of cardiovascular disease
1. Cardiovascular finding 2. Decisional Conflict 3. Smoking cessation 4. Costs and Cost Analysis 5. Prophylactic 6. Quality of Life 7. Medication adherence 8. Physical Exercises 9. At Risk 10. Adverse Event 11. Diet types
outcomes:
Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
1. Blood pressure measurement 2. Costs and Cost Analysis 3. Cholesterol Analyses 4. Quality of Life 5. Death 6. Cardiovascular disease 7. Medication adherence 8. Withdrawn 9. Adverse Event
outcomes:
Eplerenone for hypertension
1. Withdrawn From Research Study 2. All Cause Mortality 3. Myocardial Infarction 4. Stroke 5. Serious Adverse Event 6. Blood Pressure Alteration 7. Death 8. Cardiovascular Mortality 9. Adverse Event
outcomes:
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
1. Venous Thrombosis 2. Death 3. Major Bleed
outcomes:
Ranolazine for stable angina pectoris
1. Exercise Tolerance Test 2. All Cause Mortality 3. Costs and Cost Analysis 4. Angina Attack 5. Quality of Life 6. Death 7. Cardiovascular Mortality 8. Coronary Revascularisation 9. Adverse Event 10. Ekg St Segment Changes 11. Acute Myocardial Infarction
outcomes:
Beta‐blockers for hypertension
1. Withdrawn From Research Study 2. Myocardial Infarction 3. Stroke 4. Congestive Heart Failure 5. Blood Pressure Alteration 6. Coronary Heart Disease 7. Death 8. Sudden Death 9. Adverse Event 10. Transient Cerebral Ischemia
outcomes:
Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm
1. All Cause Mortality 2. Cardiovascular Event 3. Cardiovascular Mortality 4. Abdominal Aortic Aneurysm
outcomes:
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
1. Morbidity Index 2. Functional Performance And Activity 3. Left Ventricular Ejection Fraction 4. Quality of Life 5. Death 6. Adverse Event
outcomes:
Caregiver‐mediated exercises for improving outcomes after stroke
1. Activities of Daily Living 2. Mood 3. Quality of Life 4. Caregiver Burden Scale 5. Stroke Impact Scale Version 3.0 6. Length Of Stay 7. Fall 8. Walking ability 9. Barthel Index
outcomes:
Blood pressure‐lowering efficacy of reserpine for primary hypertension
1. Withdrawn From Research Study 2. Blood Pressure Alteration 3. Alteration In Heart Rate 4. Adverse Event
outcomes:
Interventions to improve adherence to lipid‐lowering medication
1. Costs and Cost Analysis 2. Medication adherence 3. Adverse Event 4. Investigations
outcomes:
Oxygen therapy for acute myocardial infarction
1. Pericarditis 2. Stroke 3. Pain 4. Cardiac Arrhythmia 5. Cardiac Failure 6. Myocardial Ischaemia Recurrent 7. Death 8. Cardiac Finding 9. Haemorrhage 10. Coronary Revascularisation
outcomes:
Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins
1. Quality of Life
outcomes:
Efficacy and safety of ablation for people with non‐paroxysmal atrial fibrillation
1. Cardiovascular finding 2. Stroke 3. Bradycardia 4. Costs and Cost Analysis 5. Atrial Arrhythmia 6. Quality of Life 7. Patient With Cardiac Pacemaker 8. Complication 9. Death 10. Hospitalization 11. Adverse Event 12. Embolism
outcomes:
Fibrates for primary prevention of cardiovascular disease events
1. Cardiovascular finding 2. Myocardial Infarction 3. Quality of Life 4. Death 5. Albuminuria
outcomes:
Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis
1. Venous Patency 2. Post-thrombotic syndrome 3. Major Bleed
outcomes:
Pharmacological interventions other than botulinum toxin for spasticity after stroke
1. Activities of Daily Living 2. Adverse Event
outcomes:
Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm
1. Cardiovascular finding 2. All Cause Mortality 3. Major Bleed
outcomes:
Self management programmes for quality of life in people with stroke
1. Self Efficacy 2. Stroke-Specific Quality of Life Scale 3. Short Form Health Survey - 36 4. Hospital Anxiety And Depression Scale 5. Stroke and Aphasia Quality of Life Scale 6. Impairment 7. Quality of Life 8. Limitation Of Activities Due To Disability 9. Euroqol
outcomes:
Venous cutdown versus the Seldinger technique for placement of totally implantable venous access ports
1. Postoperative Complication 2. Infection 3. Pneumothorax 4. Catheter 5. Complication 6. Perioperative complication
outcomes:
Intravenous heparin during ruptured abdominal aortic aneurysmal repair
1. All Cause Mortality
outcomes:
Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs
1. Distal Vessel Patency 2. Amputation 3. Death
outcomes:
Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy
1. Diseases and disorders 2. Decompensated Cardiac Failure 3. Quality of Life 4. Poisoning And Toxicity 5. Death 6. Hospitalization 7. Medication adherence 8. Adverse Event
outcomes:
Sulodexide for treating venous leg ulcers
1. Recurrent Venous Leg Ulcer 2. Costs and Cost Analysis 3. Quality of Life 4. Venous leg ulcer 5. Wound Healing 6. Adverse Event
outcomes:
Routine invasive strategies versus selective invasive strategies for unstable angina and non‐ST elevation myocardial infarction in the stent era
1. Refractory Angina 2. Myocardial Infarction 3. Death 4. Complication 5. Hospitalization
outcomes:
Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope
1. General Clinical State Finding 2. Costs and Cost Analysis 3. Syncope 4. Quality of Life 5. Death 6. Adverse Event
outcomes:
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
1. Minor Bleed 2. Venous Thrombosis 3. Pulmonary Embolism 4. Major Bleed
outcomes:
Pre‐hospital versus in‐hospital initiation of cooling for survival and neuroprotection after out‐of‐hospital cardiac arrest
1. Neurological Finding 2. Survival
outcomes:
Blood pressure lowering efficacy of beta‐1 selective beta blockers for primary hypertension
1. Withdrawn From Research Study 2. Blood Pressure Alteration 3. Finding Of Arterial Pulse Pressure 4. Alteration In Heart Rate 5. Adverse Event
outcomes:
Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals
1. Withdrawn From Research Study 2. Myocardial Infarction 3. Sudden Cardiac Death 4. Adverse Event
outcomes:
Interventions for helping people adhere to compression treatments for venous leg ulceration
1. Recurrent Venous Leg Ulcer 2. Pain 3. Quality of Life 4. Venous leg ulcer 5. Wound Healing 6. Adverse Event
outcomes:
Calcium channel blockers for primary Raynaud's phenomenon
1. Raynaud's Phenomenon
outcomes:
Sexual counselling for sexual problems in patients with cardiovascular disease
1. Satisfactory Sexual Experience 2. Patient knowledge 3. Psychological Finding 4. Finding Relating To Sexual Activity 5. Quality of Life 6. Sexual function 7. Finding Related To Sexual Relationship 8. Patient Satisfaction
outcomes:
Oral aspirin for treating venous leg ulcers
1. All Cause Mortality 2. Venous leg ulcer 3. Wound Healing 4. Adverse Event 5. Major Bleed
outcomes:
Biphasic versus monophasic waveforms for transthoracic defibrillation in out‐of‐hospital cardiac arrest
1. Finding Of Heart Rhythm 2. Hospital discharge 3. Signs Of Return Of Spontaneous Circulation 4. Equipment Finding 5. Adverse Event 6. Survival
outcomes:
Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease
1. Costs and Cost Analysis 2. Death 3. Adverse Event 4. At Risk
outcomes:
Warfarin initiation nomograms for venous thromboembolism
1. International Normalized Ratio 2. Minor Bleed 3. Venous Thrombosis 4. Length Of Stay 5. Major Bleed
outcomes:
Perioperative angiotensin‐converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults
1. All Cause Mortality 2. Stroke 3. Congestive Heart Failure 4. Acute Myocardial Ischemia 5. Cardiac Death 6. Length Of Stay 7. Complication 8. Low Blood Pressure 9. Adverse Event 10. Acute Myocardial Infarction
outcomes:
Colchicine for prevention of cardiovascular events
1. Cardiovascular finding 2. All Cause Mortality 3. Stroke 4. Myocardial Infarction 5. Heart Failure 6. Cardiovascular Mortality 7. Hospitalization 8. Adverse Event
outcomes:
A 'test and treat' strategy for elevated wound protease activity for healing in venous leg ulcers
1. Wound Healing 2. Adverse Event
outcomes:
Internet‐based interventions for the secondary prevention of coronary heart disease
1. Blood pressure measurement 2. Costs and Cost Analysis 3. Lipid Tests 4. Quality of Life 5. Lifestyle 6. Death 7. Infarction 8. Medication adherence 9. Adverse Event 10. Coronary Revascularisation
outcomes:
Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction
1. Costs and Cost Analysis 2. Quality of Life 3. Death 4. Hospitalization 5. Therapeutic Procedures NEC 6. Adverse Event
outcomes:
Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death
1. All Cause Mortality 2. Sudden Cardiac Death 3. Quality of Life 4. Cardiac Death 5. Adverse Event
outcomes:
Aminophylline for bradyasystolic cardiac arrest in adults
1. Disease-Free Survival 2. Signs Of Return Of Spontaneous Circulation 3. Hospital admission 4. Neurological Finding 5. Adverse Event 6. Survival
outcomes:
Structured telephone support or non‐invasive telemonitoring for patients with heart failure
1. Costs and Cost Analysis 2. Patient knowledge 3. Attitude 4. Quality of Life 5. Death 6. Hospitalization 7. Patient compliance
outcomes:
Fibrates for secondary prevention of cardiovascular disease and stroke
1. Stroke 2. Myocardial Infarction 3. Costs and Cost Analysis 4. Quality of Life 5. Death 6. Adverse Event 7. Investigations
outcomes:
Implantable defibrillators versus medical therapy for cardiac channelopathies
1. Cardiovascular finding 2. All Cause Mortality 3. Costs and Cost Analysis 4. Quality of Life 5. Disorder Of Implantable Defibrillator 6. Adverse Event
outcomes:
Stent graft types for endovascular repair of thoracic aortic aneurysms
1. Death
outcomes:
Debridement for venous leg ulcers
1. Debridement 2. Wound Healing
outcomes:
Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
1. Stroke 2. All Cause Mortality 3. Recurrent Transient Cerebral Ischemic Attack 4. Ischemic Stroke 5. Adverse Event 6. Atrial Fibrillation 7. Transient Ischemia
outcomes:
Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension
1. Withdrawn From Research Study 2. Blood Pressure Alteration 3. Alteration In Heart Rate 4. Adverse Event
outcomes:
Prophylactic lidocaine for myocardial infarction
1. Death 2. Ventricular Fibrillation 3. Adverse Event
outcomes:
Buflomedil for acute ischaemic stroke
1. Disability 2. Chinese Stroke Scale 3. Death 4. Physical Functional Dependency 5. Barthel Index 6. Clinical Improvement
outcomes:
Negative pressure wound therapy for treating leg ulcers
1. Leg Ulcer 2. Wound Healing 3. Adverse Event
outcomes:
Fresh frozen plasma for cardiovascular surgery
1. Coagulation factor measurement 2. Transfusion 3. Complication 4. Death 5. Red Blood Cell Transfusion 6. Adverse Event
outcomes:
Psychosocial interventions for smoking cessation in patients with coronary heart disease
1. Stopped Smoking
outcomes:
Interventions for post‐stroke fatigue
1. Visual Analog Fatigue Scale 2. Energy 3. Assessment Of Fatigue 4. Fatigue Severity Scale 5. Patient-Reported Outcome
outcomes:
Psychological interventions for symptomatic management of non‐specific chest pain in patients with normal coronary anatomy
1. Cardiovascular finding 2. Pain Scale 3. Psychological Finding 4. Attitude 5. Quality of Life 6. Death 7. Hospitalization 8. At Risk 9. Pain Intensity
outcomes:
Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
1. Venous Thrombosis 2. Major Bleed
outcomes:
Motivational interviewing for improving recovery after stroke
1. Katz Activities Of Daily Living 2. Functional Independence Measure 3. Modified Rankin Scale 4. Barthel Index 5. Rehabilitation Activities Profile
outcomes:
Anti‐inflammatory treatment for carditis in acute rheumatic fever
1. Erythrocyte Sedimentation Rate 2. C-reactive Protein level 3. Hospitalization 4. Lesion
outcomes:
Blood pressure‐lowering efficacy of loop diuretics for primary hypertension
1. Creatinine 2. Withdrawn From Research Study 3. Uric acid measurement 4. Blood Pressure Alteration 5. Serum Potassium 6. Glucose 7. Measurement Of Serum Lipid Level 8. Adverse Event
outcomes:
Adenosine and verapamil for no‐reflow during primary percutaneous coronary intervention in people with acute myocardial infarction
1. Myocardial Infarction 2. Costs and Cost Analysis 3. Myocardial Finding 4. Quality of Life 5. Death 6. Adverse Event
outcomes:
Influenza vaccines for preventing cardiovascular disease
1. Myocardial Infarction 2. Angina Pectoris 3. Death
outcomes:
Intra‐aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock
1. Cardiovascular finding 2. Quality of Life 3. Haematology Investigations 4. Complication 5. Death 6. Hospitalization
outcomes:
Anaesthetic and sedative agents used for electrical cardioversion
1. Serious Adverse Event 2. Apnea 3. Awareness During Anaesthesia 4. Low Blood Pressure
outcomes:
Interventions for improving community ambulation in individuals with stroke
1. Self Efficacy 2. Therapy Outcome Measure Participation Scale 3. 6-minute Walk Test 4. Gait Speed 5. Quality of Life 6. Walk Test
outcomes:
Atorvastatin for lowering lipids
1. Withdrawn From Research Study 2. High Density Lipoprotein Cholesterol Measurement 3. Triglycerides Measurement 4. Total Cholesterol Measurement 5. Low Density Lipoprotein Cholesterol Measurement 6. Adverse Event
outcomes:
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass
1. Renal Replacement 2. Acute Renal Failure 3. Serum Creatinine 4. Death 5. Adverse Event
outcomes:
Transmyocardial laser revascularization versus medical therapy for refractory angina
1. Myocardial Perfusion 2. Exercise Tolerance Finding 3. Angina Pectoris 4. Quality of Life 5. Death
outcomes:
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery
1. Coronary Graft Patency
outcomes:
Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia
1. Cardiovascular finding 2. Sinus Rhythm 3. Death 4. Adverse Event
outcomes:
Beta‐adrenergic blockers for perioperative cardiac risk reduction in people undergoing vascular surgery
1. All Cause Mortality 2. Myocardial Infarction 3. Cardiovascular observations
outcomes:
Statins for primary prevention of venous thromboembolism
1. Venous Thrombosis
outcomes:
Biologics, colchicine, corticosteroids, immunosuppressants and interferon‐alpha for Neuro‐Behçet's Syndrome
1. Withdrawal Due To Adverse Events 2. Adverse Event 3. Patient-Reported Outcome
outcomes:
Balloon angioplasty, with and without stenting, versus medical therapy for hypertensive patients with renal artery stenosis
1. Creatinine Clearance 2. Blood Pressure 3. Serum Creatinine 4. Estimated glomerular filtration rate
outcomes:
Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension
1. Withdrawn From Research Study 2. Blood Pressure Alteration 3. Finding Of Arterial Pulse Pressure 4. Alteration In Heart Rate 5. Adverse Event
outcomes:
Rosuvastatin for lowering lipids
1. Withdrawn From Research Study 2. High Density Lipoprotein Cholesterol Measurement 3. Triglycerides Measurement 4. Non-HDL Cholesterol 5. Total Cholesterol Measurement 6. Low Density Lipoprotein Cholesterol Measurement 7. Adverse Event
outcomes:
Interventions for deliberately altering blood pressure in acute stroke
1. Disability 2. Death
outcomes:
Cardiopulmonary resuscitation (CPR) plus delayed defibrillation versus immediate defibrillation for out‐of‐hospital cardiac arrest
1. Signs Of Return Of Spontaneous Circulation 2. Neurological Finding 3. Survival
outcomes:
Pre‐hospital versus in‐hospital thrombolysis for ST‐elevation myocardial infarction
1. All Cause Mortality 2. Stroke 3. Allergic Reaction 4. Complication 5. Ventricular Fibrillation 6. Haemorrhage
outcomes:
Time course for blood pressure lowering of dihydropyridine calcium channel blockers
1. Systolic Blood Pressure 2. Diastolic Blood Pressure 3. Blood Pressure
outcomes:
Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension
1. Withdrawn From Research Study 2. All Cause Mortality 3. Stroke 4. Myocardial Infarction 5. Congestive Heart Failure 6. Cardiovascular Event 7. Coronary Heart Disease 8. Sudden Cardiac Death 9. Adverse Event
outcomes:
Exercise for people with high cardiovascular risk
1. Stroke 2. All Cause Mortality 3. Cardiovascular Mortality 4. Acute Myocardial Infarction
outcomes:
Heparin versus placebo for non‐ST elevation acute coronary syndromes
1. Myocardial Infarction 2. All Cause Mortality 3. Recurrent Angina After Coronary Stent Placement 4. Heart Revascularization 5. Hemorrhage
outcomes:
Angioplasty versus bare metal stenting for superficial femoral artery lesions
1. Aortic restenosis
outcomes:
Anticoagulation therapy versus placebo for pulmonary hypertension
1. 6-minute Walk Test 2. Death 3. Hemorrhage
outcomes:
Blood pressure‐lowering efficacy of monotherapy with thiazide diuretics for primary hypertension
1. Blood pressure measurement 2. Creatinine 3. Withdrawn From Research Study 4. Uric Acid 5. Serum Potassium 6. Measurement Of Serum Lipid Level 7. Adverse Event
outcomes:
Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
1. Serology Positive 2. Cardiomyopathy 3. Xenodiagnosis 4. Polymerase Chain Reaction 5. Parent-Reported Outcome 6. Electrocardiographic Monitoring 7. Death
outcomes:
Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication
1. Pain 2. Walking Distance
outcomes:
Type of incision for below knee amputation
1. Reamputation 2. Prosthetic Limb Replacement 3. Postoperative Infection 4. Healing
outcomes:
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation
1. Ischemic Stroke 2. Cardiovascular Mortality 3. Adverse Event
outcomes:
Glycoprotein IIb‐IIIa inhibitors for acute ischaemic stroke
1. Death 2. Rankin Disability Scale